TPG and CPP acquire IMS Health


IMS Health, which claims to be the global leader in market intelligence for the pharmaceutical and health industries, has announced that its board of directors has unanimously approved the sale of the firm for USD5.2bn, including debt, to a consortium of investment funds managed by TPG Capital (USD45bn in assets) and Canada Pension Plan Investment Board (CPP IB, USD116.6bn in assets, of which USD18.4bn are in private equity). Shareholders will receive USD22 per share in cash, which represents a premium of about 50% over their closing price on 16 October, the last day before rumours broke that IMS was studying variuos strategic options, and 31% over their closing price on Thursday. TPG and CPP IB will finance the transaction with equity and debt provided by affiliates of Goldman Sachs.